迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02493 迈威生物-B

午间休市 06-30 11:50:37

23.400

-0.500

-2.09%

最高24.300	最低22.060	成交量24.32万
今开22.060	昨收23.900	日振幅9.37%
总市值104.60亿	流通市值11.03亿	总股本4.47亿
成交额579.91万	换手率0.52%	流通股本4,713万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":23.4,"timestamp":1782791437709,"preClose":23.9,"halted":0,"volume":243200,"delay":0,"changeRate":-0.020920502092050212,"floatShares":47130200,"shares":447000000,"eps":-2.804520500674468,"marketStatus":"午间休市","change":-0.5,"latestTime":"06-30 11:50:37","open":22.06,"high":24.3,"low":22.06,"amount":5799128,"amplitude":0.093724,"askPrice":23.66,"askSize":200,"bidPrice":23.4,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-2.6902622580543967,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782795600000},"marketStatusCode":3,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":23.9,"openAndCloseTimeList":[[1782783000000,1782792000000],[1782795600000,1782806400000]],"volumeRatio":0.860304,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":28.25,"timestamp":1782790200000,"preClose":28.47,"halted":0,"volume":6511100,"delay":0,"premium":"-28.23"}},"requestUrl":"/m/hq/s/02493","defaultTab":"news","newsList":[{"id":"2646648337","title":"迈威生物跌6.85% 2022年上市募34.77亿国泰海通保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2646648337","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646648337?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:03","pubTimestamp":1782460982,"startTime":"0","endTime":"0","summary":"中国经济网北京6月26日讯 迈威生物 今日收报25.82元，跌幅6.85%。　　迈威生物首次公开发行股票的发行费用合计1.85亿元，其中，保荐承销费1.55亿元。　　迈威生物披露的上市公告书显示，海通证券安排子公司海通创新证券投资有限公司参与本次发行战略配售，配售数量为本次公开发行数量的2.88%，即287.3563万股，获配金额9999.9992万元；海通创新证券投资有限公司本次跟投获配股票的限售期为24个月，限售期自本次公开发行的股票在上交所上市之日起开始计算。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260626/32291042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1564","BK0183","BK0028","BK0201","601211","BK1161","BK0012","BK1147","BK0184","02493","02611","BK0188","IPOS","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646646809","title":"迈威生物（688062）披露首次公开发行部分限售股上市流通公告，6月25日股价上涨0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646646809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646646809?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:27","pubTimestamp":1782397637,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，迈威生物报收于27.72元，较前一交易日上涨0.14%，最新总市值为123.83亿元。近日，迈威（上海）生物科技股份有限公司发布《首次公开发行部分限售股上市流通公告》。公告显示，公司首次公开发行部分限售股将于2026年7月3日上市流通，本次上市流通数量为26,070,000股，占公司A股股本的6.52%，占总股本的5.84%。上述股东已履行相关承诺，保荐机构对本次限售股上市流通无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","02493","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645894983","title":"迈威生物：9MW5211注射液两项适应症临床试验获批 覆盖多发性硬化、炎症性肠病","url":"https://stock-news.laohu8.com/highlight/detail?id=2645894983","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645894983?lang=zh_cn&edition=full","pubTime":"2026-06-24 18:15","pubTimestamp":1782296100,"startTime":"0","endTime":"0","summary":"6月24日，迈威生物（688062/02493）发布公告，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于多发性硬化（MS）适应症的临床试验申请获得批准。此外，9MW5211用于炎症性肠病（IBD）适应症的临床试验申请也已获得批准，且公司正在积极推进其他多个适应症的临床试验申请工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781539226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645880777","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645880777","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645880777?lang=zh_cn&edition=full","pubTime":"2026-06-23 18:37","pubTimestamp":1782211020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请获得批准。6MW5311是基于公司T Cell Engager(TCE)技术平台开发的一款靶向LILRB4/CD3的双特异性抗体，拟开发适应症为：血液瘤(AML、CMML以及MM)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688062","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073615","title":"迈威生物（688062）披露召开2025年度暨2026年第一季度业绩说明会公告，6月22日股价下跌1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073615?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:31","pubTimestamp":1782138678,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，迈威生物报收于27.08元，较前一交易日下跌1.24%，最新总市值为120.97亿元。该股当日开盘27.01元，最高27.16元，最低25.66元，成交额达2.55亿元，换手率为4.72%。近日，迈威（上海）生物科技股份有限公司发布《关于召开2025年度暨2026年第一季度业绩说明会的公告》。公告显示，公司将于2026年6月30日10:00-11:00通过网络互动方式在“价值在线”平台举办业绩说明会。会议结束后可通过平台查看召开情况及主要内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200038998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK0239","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644855066","title":"每周股票复盘：迈威生物（688062）9MW2821临床数据亮相ESMO Gynae","url":"https://stock-news.laohu8.com/highlight/detail?id=2644855066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644855066?lang=zh_cn&edition=full","pubTime":"2026-06-20 03:24","pubTimestamp":1781897051,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，迈威生物报收于27.42元，较上周的28.53元下跌3.89%。本周，迈威生物6月15日盘中最高价报28.25元。公司公告汇总：9MW2821在ESMO Gynae以口头报告形式公布宫颈癌临床数据。职工代表大会选举桂勋先生为第三届董事会职工代表董事，其任期自非职工代表董事就任之日起至本届董事会任期届满。迈威生物在2026年欧洲肿瘤内科学会妇科肿瘤年会上以口头报告和壁报形式公布9MW2821治疗复发性或转移性宫颈癌的最新临床数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000002013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688062","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644815380","title":"迈威生物-B(02493)：华俊获委任为授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2644815380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644815380?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:02","pubTimestamp":1781791376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，自2026年6月18日起：胡会国先生不再担任公司于香港联合交易所有限公司证券上市规则第3.05条项下授权代表的职务;及公司的执行董事华俊先生获委任为授权代表。于华俊先生获委任后，公司的授权代表为华俊先生及梁君慧女士。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644276089","title":"迈威生物-B(02493)：桂勋获选举为职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2644276089","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644276089?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:50","pubTimestamp":1781790608,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物-B(02493)发布公告，于2026年6月18日召开的工会委员会上，桂勋博士在公司于2026年6月18日举行的第一届工会委员会第七次会议暨公司职工代表大会上获选举为公司第三届董事会职工代表董事。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208599","title":"迈威生物完成董事会换届：刘大涛当选董事长并任总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208599","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644208599?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:27","pubTimestamp":1781785620,"startTime":"0","endTime":"0","summary":"6月18日，迈威生物（688062/02493）发布公告，公司召开会议完成第三届董事会的换届选举，其中刘大涛被选为董事长，桂勋被选为职工代表董事。此外，公司聘任了多名高级管理人员，刘大涛担任总经理，HAIWU（武海）、桂勋、王树海、胡会国、李瀚等担任副总经理，华俊任副总经理、财务负责人，王鹤飞任董事会秘书，高戈任证券事务代表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606183776363418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644797482","title":"港股异动 | 迈威生物-B(02493)涨超3% 旗下迈威视与维眸生物达成战略合作 聚焦眼科炎症及眼免疫领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2644797482","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644797482?lang=zh_cn&edition=full","pubTime":"2026-06-17 11:38","pubTimestamp":1781667515,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B涨超3%，截至发稿，涨2.72%，报26.48港元，成交额648.46万港元。消息面上，6月16日，据迈威生物官微消息，公司宣布其控股子公司迈威视与国内领先的眼科小分子药物研发企业维眸生物达成战略合作。据介绍，迈威生物视拥多款眼底产品，包括9MW0211抗VEGF单抗创新药、阿达木单抗生物类似药、阿柏西普生物类似药，并覆盖眼免疫药物、眼底病药物、以及干眼和眼表等领域的成熟药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02493","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217232","title":"港股异动 | 迈威生物-B(02493)午前涨超6% 注射用6MW5311临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217232","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643217232?lang=zh_cn&edition=full","pubTime":"2026-06-15 11:51","pubTimestamp":1781495491,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B午前涨超6%，截至发稿，涨6.22%，报26.66港元，成交额1256.09万港元。消息面上，迈威生物-B发布公告，近日，迈威(上海)生物科技股份有限公司收到美国食品药品监督管理局签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","BK1161","BK4588","LABU","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642026565","title":"迈威生物(688062.SH)：注射用6MW5311临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2642026565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642026565?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:25","pubTimestamp":1781252747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》，注射用6MW5311用于血液瘤(急性髓系白血病(AML)、慢性粒单核细胞白血病(CMML)以及多发性骨髓瘤(MM))适应症的临床试验申请正式获得FDA许可。此外，6MW5311临床试验申请已获得国家药品监督管理局受理。6MW5311为全球首款获批开展临床试验的靶向LILRB4/CD3的TCE创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02493","LABU","BK1161","BK4588","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642018724","title":"港股异动 | 迈威生物-B(02493)再涨超7% 全球首个清除型抗体获批临床 用于治疗炎症性肠病","url":"https://stock-news.laohu8.com/highlight/detail?id=2642018724","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642018724?lang=zh_cn&edition=full","pubTime":"2026-06-11 14:39","pubTimestamp":1781159980,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B再涨超7%，截至发稿，涨5.71%，报25.9港元，成交额4853.7万港元。消息面上，6月4日，迈威生宣布其自主研发的抗体创新药9MW5211注射液正式获得中国国家药品监督管理局批准，可针对炎症性肠病开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","BK4588","02493","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642411530","title":"港股异动 | 迈威生物-B(02493)逆市涨超7% 9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642411530","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642411530?lang=zh_cn&edition=full","pubTime":"2026-06-10 10:09","pubTimestamp":1781057355,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迈威生物-B逆市涨超7%。截至发稿，涨6.54%，报23.78港元，成交额860.25万港元。消息面上，迈威生物近期宣布，公司自主研发的抗体创新药9MW5211正式获得国家药品监督管理局批准，可针对炎症性肠病开展临床试验。9MW5211在其靶点上是全球首款进入临床阶段的候选药物。此前，9MW5211已获FDA许可在美国开展针对IBD的临床试验。两项研究均展现出令人鼓舞的疗效及良好的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","02493","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127863","title":"每周股票复盘：迈威生物（688062）召开两次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127863?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:58","pubTimestamp":1780768691,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，迈威生物报收于26.6元，较上周的30.4元下跌12.5%。本周，迈威生物6月1日盘中最高价报31.44元。本周关注点来自公司公告汇总：迈威生物召开2026年第二次临时股东会，审议通过申请注册发行定向债务融资工具的议案。公司公告汇总迈威（上海）生物科技股份有限公司于2026年6月1日召开2026年第二次临时股东会，会议由董事会召集，董事长刘大涛主持，采用现场与网络投票结合方式召开。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239","02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171924678","title":"迈威生物-B 2026年5月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1171924678","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171924678?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:05","pubTimestamp":1780617939,"startTime":"0","endTime":"0","summary":"迈威（上海）生物科技股份有限公司于2026年6月5日发布2026年5月股份变动月报表，报告期为2026年5月1日至2026年5月31日。公告显示，公司本期无新发行股份或其他股本变动情况，股本结构保持稳定。最后，公司声明已严格遵守适用的香港联交所《上市规则》及其他相关法律法规进行相关证券发行或股份变动事宜，并及时向监管机构递交报告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640615959","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640615959","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640615959?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:05","pubTimestamp":1780567515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于炎症性肠病适应症的临床试验申请获得批准，此外，其用于IBD适应症的美国临床试验申请已获得FDA许可，用于多发性硬化等多个适应症的临床试验申请获得国家药品监督管理局受理，公司亦在积极推进其他适应症临床试验申请工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640897041","title":"从ASCO数据到迈卫健扩围：迈威生物创新与商业化并进","url":"https://stock-news.laohu8.com/highlight/detail?id=2640897041","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640897041?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:20","pubTimestamp":1780478447,"startTime":"0","endTime":"0","summary":"从ASCO上的亮眼数据，到ESMO GC即将揭晓的宫颈癌数据，再到迈卫健的适应症“扩围”:迈威生物在短时间内打出了一套漂亮的“组合拳”。","market":"sh","thumbnail":"https://img2.gelonghui.com/d273d-c22ea71a-0f20-4fd3-9fb7-a14ae8e7ce94.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-c22ea71a-0f20-4fd3-9fb7-a14ae8e7ce94.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5047096","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","02493","BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640391139","title":"迈威生物（688062）披露关于申请注册发行定向债务融资工具的议案获通过，6月2日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640391139","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640391139?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:42","pubTimestamp":1780393357,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，迈威生物报收于28.51元，较前一交易日下跌1.62%，最新总市值为127.36亿元。该股当日开盘28.88元，最高29.26元，最低27.71元，成交额达2.16亿元，换手率为3.73%。公告显示，公司于2026年6月1日召开2026年第二次临时股东会，审议通过《关于申请注册发行定向债务融资工具的议案》。该议案为普通决议议案，已获出席股东所持表决权过半数通过。出席会议股东共131人，代表有表决权股份201,449,250股，占公司总表决权股份的45.2148%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640966924","title":"股市必读：迈威生物（688062）今年截至6月1日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640966924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640966924?lang=zh_cn&edition=full","pubTime":"2026-06-02 01:38","pubTimestamp":1780335489,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，迈威生物报收于28.98元，下跌4.67%，换手率4.5%，成交量9.18万手，成交额2.74亿元。当日关注点来自交易信息汇总：迈威生物股价报28.98元，跌4.67%，已连续5日下跌，年内累计跌幅达25.41%。来自公司公告汇总：迈威生物召开2026年第二次临时股东会，审议通过申请注册发行定向债务融资工具的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200001375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mabwell.com","stockEarnings":[{"period":"1week","weight":-0.0947},{"period":"1month","weight":0.0492},{"period":"3month","weight":-0.1353},{"period":"ytd","weight":-0.1353}],"compareEarnings":[{"period":"1week","weight":-0.0312},{"period":"1month","weight":-0.0856},{"period":"3month","weight":-0.0711},{"period":"6month","weight":-0.1016},{"period":"1year","weight":-0.0518},{"period":"ytd","weight":-0.1016}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家全产业链布局的创新型生物制药公司,始终秉承“让创新从梦想变成现实”的愿景,践行“探索生命,惠及健康”的使命,通过源头创新,为患者提供疗效更好、可及性更强的生物创新药,满足全球未被满足的临床需求。公司主营业务为研发、生产以及销售创新型药物和生物类似药。公司主要产品为抗体、ADC药物和重组蛋白、小分子化学药等药物。公司荣誉:上海产业人才队伍建设工作“优秀案例奖”、澳洲会计师公会“认可雇主”、星耀榜“2021中国生物创新药最具成长性年度大奖”、中国医药人才品牌榜总榜及最具竞争力品牌等。","exchange":"SEHK","name":"迈威生物-B","nameEN":"MABWELL-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-B,02493,迈威生物-B股票,迈威生物-B股票老虎,迈威生物-B股票老虎国际,迈威生物-B行情,迈威生物-B股票行情,迈威生物-B股价,迈威生物-B股市,迈威生物-B股票价格,迈威生物-B股票交易,迈威生物-B股票购买,迈威生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-B(02493)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-B(02493)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}